Crosspoint Capital Strategies’s DexCom DXCM Stock Holding History

Crosspoint Capital Strategies’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.34M	Buy	+11,816	New	+$1.3M	2.65%	10
2015 Q4	–	Sell	-380	Closed	-$8K	–	1050
2015 Q3	$8K	Sell	380 -2,468	-87%	-$55.1K	0.01%	435
2015 Q2	$57K	Buy	+2,848	New	+$50K	0.02%	336
2015 Q1	–	Sell	-1,424	Closed	-$20K	–	568
2014 Q4	$20K	Buy	+1,424	New	+$17.4K	0.01%	442
2014 Q2	–	Sell	-545,212	Closed	-$5.64M	–	545
2014 Q1	$5.64M	Buy	545,212 +4,268	+0.8%	+$44.1K	2.28%	12
2013 Q4	$6.34M	Buy	+540,944	New	+$4.28M	2.11%	6

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crosspoint Capital Strategies's DXCM Position: Q4 2022 in Review

Crosspoint Capital Strategies opened a new position in DexCom (DXCM) in Q4 2022: 11,816 shares worth $1.34M. The stake represents 2.65% of the portfolio and ranks #10 among its holdings. This is a return to the name: Crosspoint Capital Strategies previously reported a position in DXCM as recently as Q3 2015.

Crosspoint Capital Strategies first reported a position in DXCM in Q4 2013 and has held it in 6 quarters since. The position peaked at $6.34M in Q4 2013. 919 funds tracked by Wall St. Rank hold DXCM as of Q4 2022.

Crosspoint Capital Strategies held 11,816 shares of DexCom worth $1.34M as of Q4 2022.
DexCom was a new Crosspoint Capital Strategies position in Q4 2022.
DexCom made up 2.65% of Crosspoint Capital Strategies's portfolio in Q4 2022, its #10 holding.
Crosspoint Capital Strategies first reported a position in DexCom in Q4 2013 and has held it in 6 quarters since.
Crosspoint Capital Strategies's DexCom position peaked at $6.34M in Q4 2013.
919 funds tracked by Wall St. Rank held DexCom as of Q4 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2022, filed 13 Feb 2023.